Pseudomonas Aeruginosa Infection Treatment Market Size (2024 - 2029)

Pseudomonas Aeruginosa Infection Treatment Market Analysis

The Pseudomonas aeruginosa infection treatment market is expected to register a CAGR of 4.7% during the forecast period.

The market expanded during COVID-19 because some of the patients who received COVID-19 therapy in hospitals and other healthcare institutions had pseudomonas aeruginosa infections as a result of the use of ventilators and other medical devices. According to the study published in Cell Reports in August 2021, it was found that Pseudomonas aeruginosa, a common coinfecting infection in COVID-19 patients, causes illness aggravation. Pseudomonas aeruginosa abundance increases with SARS-CoV-2 viral RNA load. Individuals infected with P. aeruginosa and suffering from COVID-19 pneumonia were given "oral ciprofloxacin" drug formulations. Thus, the studies demonstrated that COVID-19 had a favourable impact on the growth of the studied market. However, the COVID-19 infection cases have been subsidized currently, studied market is expected to project stable growth over the forecast period due to the rising burden of pseudomonas aeruginosa infection.

The major factors such as the increasing incidence of infections associated with it such as pneumonia, cystic fibrosis, and urinary tract infections, the increasing development of products, increasing antibacterial resistance, and growing R&D activities are driving the growth of the Pseudomonas aeruginosa infection market.

The prevalence of hospital-acquired infections has increased in recent years. According to an article published in the National Library of Medicine in August 2022, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 and 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. As a result of the increased burden of P. aeruginosa infection, the demand for its treatment is predicted to rise over the projection period, thereby boosting the growth of the studied market.

Furthermore, growing research and development activities on pseudomonas aeruginosa infection are expected to support market expansion over the forecast period. For instance, according to ClinicalTrials.gov updated in October 2022, a study titled "A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa" is under phase II trials and expected to be completed by 2024. Thus, such a study is expected to bring an advanced product for treating pseudomonas aeruginosa infection, thereby boosting the market's growth.

Various organic and inorganic strategies by the market players are likely to support the growth of the market. For instance, in April 2021, UK-based Phico Therapeutics secured an initial USD 5.3 million grant from CARB-X for developing intravenous-engineered bacteriophage drugs to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa.

Thus, all the aforementioned factors, such as the growing prevalence of pseudomonas aeruginosa infection and rising drug development and discovery activities, are expected to propel the growth of the market over the forecast period. However, drug resistance ability of pseudomonas aeruginosa may restraint the market growth over the forecast period.

Pseudomonas Aeruginosa Infection Treatment Industry Segmentation

As per the scope of the report, pseudomonas aeruginosa is a rod-shaped, encapsulated, Gram-negative bacteria that causes diseases in humans. It infects people with weakened immune systems causing “blue-green pus bacteria” associated with hospital-acquired infections such as ventilator-associated pneumonia and sepsis. Pseudomonas aeruginosa infection treatment drugs inhibit the growth of Pseudomonas aeruginosa or completely eliminate the bacterium. The Pseudomonas Aeruginosa Infection Treatment Market is Segmented by Treatment (Monotherapy and Combination Therapy), Route of Administration (Nasal, Oral, and Intravenous), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for all the above segments.